Loading…
Loading grant details…
| Funder | Wellcome Trust |
|---|---|
| Recipient Organization | University of Dundee |
| Country | United Kingdom |
| Start Date | May 01, 2021 |
| End Date | Apr 30, 2026 |
| Duration | 1,825 days |
| Number of Grantees | 1 |
| Roles | Award Holder |
| Data Source | Europe PMC |
| Grant ID | 221914 |
IL-33 is a critical cytokine in allergy, obesity, helminth infection, sepsis, and respiratory viral infection.
Blockade of IL-33 (or its receptor, ST2) is currently being trialled in a range of allergic and inflammatory conditions, including Covid-19. The cytokine has a short half-life on release, but conversely has effects at distal sites and over long periods.
Furthermore, innate immune cells in the intestine are poorly responsive to IL-33, but susceptibility to intestinal helminths is strongly controlled by IL-33.
This project will investigate: 1) How, at a protein structural level, parasite proteins effectively block IL-33 responses.
Determination of the effects on the parasite and host of blocking parasite modulation of the IL-33 pathway. 2) What are the roles and targets of IL-33 released from the intestinal epithelium, both locally (in parasite infection) and systemically (in diet-induced obesity). 3) The role of soluble IL-33 receptor in stabilisation of IL-33, and its effects at distal sites.
To achieve these aims will we will use structural biology, in vivo models of IL-33-dependent responses, creation of cell-specific ST2-deficient mouse strains, and generation of a soluble ST2-deficient mouse.
Finally we will use human blood samples and three-dimensional culture methods to ensure translation of these findings to humans.
University of Dundee
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant